These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
569 related items for PubMed ID: 28241822
1. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Cardiovasc Diabetol; 2017 Feb 27; 16(1):29. PubMed ID: 28241822 [Abstract] [Full Text] [Related]
2. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. Davies MJ, Merton K, Vijapurkar U, Yee J, Qiu R. Cardiovasc Diabetol; 2017 Mar 21; 16(1):40. PubMed ID: 28327140 [Abstract] [Full Text] [Related]
3. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials. Liu J, Pong A, Gallo S, Darekar A, Terra SG. Cardiovasc Diabetol; 2019 May 07; 18(1):59. PubMed ID: 31064361 [Abstract] [Full Text] [Related]
6. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE. Diabetes Obes Metab; 2015 Dec 07; 17(12):1180-93. PubMed ID: 26343814 [Abstract] [Full Text] [Related]
10. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. John M, Cerdas S, Violante R, Deerochanawong C, Hassanein M, Slee A, Canovatchel W, Hamilton G. Int J Clin Pract; 2016 Sep 07; 70(9):775-85. PubMed ID: 27600862 [Abstract] [Full Text] [Related]
13. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Stenlöf K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R, Tong C, Canovatchel W, Meininger G. Curr Med Res Opin; 2014 Feb 07; 30(2):163-75. PubMed ID: 24073995 [Abstract] [Full Text] [Related]
14. Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity. Davidson JA, Aguilar R, Lavalle González FJ, Trujillo A, Alba M, Vijapurkar U, Meininger G. Ethn Dis; 2016 Apr 21; 26(2):221-8. PubMed ID: 27103773 [Abstract] [Full Text] [Related]
16. Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension. Townsend RR, Machin I, Ren J, Trujillo A, Kawaguchi M, Vijapurkar U, Damaraju CV, Pfeifer M. J Clin Hypertens (Greenwich); 2016 Jan 21; 18(1):43-52. PubMed ID: 26663712 [Abstract] [Full Text] [Related]
18. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Rodbard HW, Seufert J, Aggarwal N, Cao A, Fung A, Pfeifer M, Alba M. Diabetes Obes Metab; 2016 Aug 21; 18(8):812-9. PubMed ID: 27160639 [Abstract] [Full Text] [Related]